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Abstract
Fibrotic tissue in the liver is mainly composed of collagen. Fibronectin, which is also present in fibrotic matrices, is required for
collagen matrix assembly in vitro. It also modulates the amount of growth factors and their release from the matrix. We
therefore examined the effects of the absence of fibronectin on the development of fibrosis in mice. Conditional deletion of
fibronectin in the liver using the Mx promoter to drive cre expression resulted in increased collagen production and hence a
more pronounced fibrosis in response to dimethylnitrosamine in mice. Exclusive deletion of fibronectin in hepatocytes or
normalization of circulating fibronectin in Mx-cKO mice did not affect the development of fibrosis suggesting a role for
fibronectinproductionbyother liver celltypes.Theboosted fibrosisinfibronectin-deficient micewas associatedwithenhanced
stellate cell activation and proliferation, elevated concentrations of active TGF-b, and increased TGF-b-mediated signaling. In
vitro experiments revealed that collagen-type-I production by fibronectin-deficient hepatic stellate cells stimulated with TGF-b
was more pronounced, and was associated with augmented Smad3-mediated signaling. Interfering with TGF-b signaling using
SB431542 normalized collagen-type-I production in fibronectin-deficient hepatic stellate cells. Furthermore, precoating culture
plates with fibronectin, but not collagen, or providing fibronectin fibrils unable to interact with RGD binding integrins via the
RGD domain significantly diminished the amount of active TGF-b in fibronectin-deficient stellate cells and normalized collagen-
type-I production in response to TGF-b stimulation. Thus, excessive stellate cell activation and production of collagen results
fromincreasedactiveTGF-bandTGF-bsignalingintheabsenceoffibronectin. Inconclusion,ourdataindicatethatfibronectin
controls the availability of active TGF-b in the injured liver, which impacts the severity of the resulting fibrosis. We therefore
propose a novel role for locally produced fibronectin in protecting the liver from an excessive TGF-b-mediated response.
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Introduction
The development of liver fibrosis is one of the early steps in the
pathogenesis of advanced liver disease and liver failure. Hepatic
stellate cells play a key role in this process by producing
extracellular matrix molecules that become incorporated in a
distorted fibrogenous network hindering normal function in
hepatocytes [1]. Transforming-growth-factor-b (TGF-b) has been
described as a major stimulator of stellate cell activation, and
hence, extracellular matrix production [2].
Fibronectin is one of the molecules produced by hepatic stellate
cells [3]. It is also part of the extracellular matrix [4]. Several
isoforms have been described and many functions have been
attributed to fibronectin. Fibronectin is important for the assembly
of a collagen matrix in vitro [5,6]. Its continuous presence also
supports matrix integrity, both in vitro and in vivo [5,7]. It further
regulates cell proliferation and cell cycle progression [8]. We have
shown that two isoforms of fibronectin reflect the severity of liver
fibrosis in patients with chronic hepatitis C raising the possibility
that fibronectin itself may play a role in the pathogenesis of fibrosis
[9].
In order to define the role of fibronectin in the liver on the
development of liver fibrosis we undertook the following study in
which fibronectin was conditionally deleted in various cell types in
mice. Liver injury was induced using dimethylnitrosamine (DMN)
and experiments on liver tissue from these mice were comple-
mented with in vitro experiments in isolated stellate cells. Our
results show that deletion of fibronectin leads to an increase in
stellate cell activation, both at baseline and after stimulation with
TGF-b. This is due to an increase in TGF-b bioavailability and
results in a more pronounced fibrosis.
Results
Deletion of fibronectin in hepatic stellate cells,
hepatocytes, Kupffer cells and endothelial cells
Hepatic stellate cells were isolated from control mice (CT) and
conditional knockout mice carrying the Mx promoter attached to
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floxed fibronectin gene. The Mx promoter was activated in vivo in
Mx-cKO mice and through the resulting expression of the
attached cre enzyme the homozygote fibronectin floxed genes
present in the cells were deleted (Figures 1A and 1B) [10]. 9762%
of the isolated hepatic stellate cells stained for either desmin or glial
fibrillary acidic protein (GFAP), both of which are markers used
for identifying stellate cells [11] suggesting a high purity. Deletion
of fibronectin was confirmed at the DNA (Figures 1A and 1B),
mRNA (Figure 1C) and protein level (Figure 1D: Western blot;
Figure 1. Evidence for successful deletion of fibronectin (FN) in vitro and in mice in vivo. Stellate, Kupffer, and endothelial cells were
isolated from Mx-conditional knockout (cKO) mice and control (CT) littermates. Stellate cells were cultured for 24 hours on plastic in the presence of
10% fibronectin-depleted fetal calf serum (FCS) (Fibronectin concentration in FCS after depletion equaled 8 ng/ml) and then collected. (A)A
simplified map of fibronectin DNA. Shown are the locations of the loxP sites around exon 1 (including the ATG sequence) and the sites of the primers
used for DNA characterization shown in 1B. The fibronectin gene is made nonfunctional by loss of the DNA between the loxP sites in the presence of
cre. (B) PCR analysis of genomic DNA shows successful deletion of the fibronectin fragment containing the ATG sequence in cKO stellate cells. (C)
mRNA expression by reverse transcription PCR shows that fibronectin expression is absent in cKO stellate cells compared to CT in the presence of
almost equivalent expression of desmin and GFAP, which are markers for stellate cells, as well as the house keeping gene GAPDH. (D) Immune
precipitation of stellate cell lysates from CT and cKO cells followed by Western blot for fibronectin shows almost absent fibronectin production in cKO
stellate cells after 4 days in culture. (E) ELISA for fibronectin in conditioned media collected from the Mx-cKO stellate cells shows lower levels of
fibronectin compared to conditioned media of littermate CT cells. Values were corrected to total protein measured by BCA. (F) Deletion of fibronectin
in vivo using the Mx-promoter results in a significant decrease in circulating fibronectin, because the Mx-promoter also deletes fibronectin in
hepatocytes, which produce most of circulating fibronectin. N=7 and 6. (G) ELISA for fibronectin in conditioned media collected from the Mx-cKO
Kupffer cells shows lower levels of fibronectin (14% of CT) compared to conditioned media of littermate CT cells. Values were corrected to total
protein measured by BCA. (H) ELISA for fibronectin in conditioned media collected from the Mx-cKO endothelial cells shows lower levels of
fibronectin (19% of CT) compared to conditioned media of littermate CT cells. Values were corrected to total protein measured by BCA.
doi:10.1371/journal.pone.0028181.g001
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media. Thus, activation of the Mx promoter successfully deleted
fibronectin in hepatic stellate cells. In addition to deleting
fibronectin in stellate cells, the activated Mx promoter can
efficiently delete fibronectin in hepatocytes, which are responsible
for the production of circulating fibronectin. Therefore, loss of
fibronectin in hepatocytes in mice that express Mx-cre and are
homozygote for floxed fibronectin can be easily confirmed by
measuring circulating plasma fibronectin, which in this case
confirmed successful deletion (Figure 1F). Other cell types that can
be affected by the activation of the Mx promoter are Kupffer and
endothelial cells. The identity of isolated Kupffer cells was
confirmed by staining with F4/80 and absence of staining with
desmin or GFAP (data not shown). ELISA of conditioned media
confirmed deletion of fibronectin to 14% of control values
(Figure 1G). The identity of isolated endothelial cells was
confirmed by positive staining with acetylated-LDL and absence
of staining with F4/80, desmin and GFAP (Data not shown).
ELISA of conditioned media also showed a decrease in fibronectin
protein to 19% of control values (Figure 1H).
Induction of liver fibrosis
We next induced liver fibrosis in cKO mice in which the Mx
promoter was activated (Mx-cKO) and control (CT) mice using
dimethylnitrosamine (DMN). ELISA of circulating fibronectin
confirmed successful deletion (Figure 2A) [12,13]. To exclude the
possibility that some fibronectin was generated in fibrotic livers by
intronic or alternate promoters we performed quantitative RT-
PCR for mRNA encoding the C-terminal part of fibronectin, the
EDA, or the EDB domain. There was more than 90% decrease in
all three products in fibrotic Mx-cKO mice compared to CT mice
(Figure S1). Fibronectin content was examined in the liver by
Western blotting (Figure 2B), which showed a difference in
fibronectin amounts between fibrotic CT and fibrotic Mx-cKO.
This was further confirmed by ELISA of liver lysates (Figure 2C).
No significant increase in the amount of fibronectin was seen after
induction of liver fibrosis in cKO animals compared to healthy
cKO mice however, further supporting the conclusion that
fibronectin deletion in the liver was successful in vivo.
Effect on extracellular matrix accumulation
DMN treatment resulted in increased sirius-red staining (i.e.,
extracellular matrix) in fibrotic-Mx-cKO mice when compared to
fibrotic CT mice (Figure 2D). Further, collagen-type-I staining
suggested that more collagen accumulated in fibrotic Mx-cKO
mice (Figure 2E-upper panel). This was confirmed using a
biochemical method measuring the amount of hydroxyproline,
which is a component and hence a marker for collagen, in liver
lysates (Figure 2E-lower panel). Using this method, healthy Mx-
cKO showed an increase in collagen (1.3-fold) compared to
healthy controls (p,0.05), while treatment with DMN resulted in
a larger increase in collagen-type-I in fibrotic-Mx-cKO (1.6-fold)
compared to fibrotic-CT (p,0.05).
Role of apoptosis
The development of liver fibrosis in response to DMN is
preceded by increased cell death leading to signals that promote
extracellular matrix accumulation [14,15]. Fibronectin may exert
antiapoptotic effects [15,16]. We therefore sought to determine
whether loss of fibronectin in Mx-cKO mice is associated with
increased apoptosis and hence increased fibrosis [14,15]. No
difference in the total number of apoptotic cells (stained with
TUNEL or with cleaved caspase 3 (ASP175)) between fibrotic Mx-
cKO and fibrotic CT livers could be detected (Figure 2F and data
not shown). Similarly, we could not detect any differences in the
levels of the liver enzymes AST or ALT that reflect hepatocyte
necrosis (Figure S2). Thus the increase in matrix accumulation in
Mx-cKO mice is not due to increased apoptosis and hence it was
not due to loss of an antiapoptotic effect of fibronectin in the liver.
Defining the cell type associated with increased matrix
accumulation in Mx-cKO mice
Hepatocytes. The Mx promoter is able to delete fibronectin
in stellate cells, hepatocytes, Kupffer cells and endothelial cells as
shown above [15] (Figure 1). In order to exclude a role of
fibronectin produced by hepatocytes themselves on the develop-
ment of fibrosis in Mx-cKO mice we deleted fibronectin in
hepatocytes exclusively using the albumin promoter (Alb-cKO).
Loss of circulating fibronectin due to successful deletion in hepato-
cytes was confirmed using ELISA (Figure 3A). The degree of liver
fibrosis in Alb-cKO and CT was similar, as determined by
measuring the amount of collagen (Figure 3B). Therefore, the
absence of fibronectin in hepatocytes in Alb-cKO does not affect
the development of fibrosis. We also administered circulating
plasma fibronectin to both CT and Mx-cKO mice, and were able
to normalize the levels of circulating fibronectin in Mx-cKO mice
(Figure S3). This did not affect the degree of fibrosis in CT mice or
prevent the increased matrix accumulation in Mx-cKO mice in
comparison to fibrotic CT mice (Figure 3C). It follows that lack of
fibronectin production in hepatocytes of Mx-cKO mice, and loss
of circulating fibronectin do not contribute to enhanced
fibrogenesis in these mice.
Inflammatory cells. We then sought to determine whether
inflammatory cells were involved in mediating increased fibrosis in
Mx-cKO mice. An increase in inflammatory cells (CD45
+) was
noted in fibrotic mice compared to healthy mice but there was no
difference between Mx-cKO and CT in either the healthy or the
fibrotic pairs (Figure 3D). This indicates that fibronectin does not
affect the infiltration of inflammatory cells in response to DMN.
Hepatic stellate cells. In order to examine the role of
stellate cells on fibrosis development in Mx-cKO mice staining for
a-SMA was performed. a-SMA has been used as a marker for
stellate cell activation but it also stains smooth muscle cells [17].
There was a significant increase in the number of a-SMA-positive
cells in both fibrotic and healthy Mx-cKO mice compared to
fibrotic and healthy controls respectively (Figure 3E). This increase
was associated with an increase in proliferation (as evidenced by
co-staining for GFAP and Ki-67) in fibrotic Mx-cKO mice
compared to fibrotic CT mice (5% vs. 1%, p,0.05) (Figure 3F). In
contrast there was no difference in apoptosis (as evidenced by co-
staining for GFAP and TUNEL and for GFAP and cleaved
caspase 3 (ASP175)) between fibrotic Mx-cKO mice and fibrotic
CT mice (Figure S4 and data not shown). We therefore conclude
that the increase in matrix accumulation in Mx-cKO is associated
with an increase in proliferation and activation of stellate cells
in vivo.
Establishing a causal relationship between deletion of
fibronectin in stellate cells and increased matrix
production
Response of cKO stellate cells to TGF-b. As shown
previously, in vivo data had suggested enhanced stellate cell
activation and increased collagen production in both healthy and
fibrotic Mx-cKO mice compared to their respective controls
(Figures 3E and 2E). In order to firmly establish a role for stellate
cells lacking fibronectin in mediating increased matrix production
in vivo, these cells were isolated and examined in vitro. a-SMA
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revealed that Mx-cKO cells had a higher baseline expression of a-
SMA after 24 hours of culture on plastic and even more so after
48 hours compared to controls (FN fl/fl or Alb-cre FN fl/fl lacking
fibronectin in the circulation only) (Figure 4A), suggesting
increased activation. Collagen-type-I relative mRNA expression
in cultured stellate cells at baseline was also significantly increased
in Mx-cKO cells when compared to CT or Alb-cKO, as measured
by qPCR (Figure 4B). We then stimulated stellate cells with TGF-b
because it is a major fibrogenic mediator in the liver [2,18].
Stellate cells cultured on plastic for 24 hours after isolation in the
presence of fibronectin-depleted serum were treated with different
doses of TGF-b for an additional 24 hours. This resulted in
significantly higher collagen-type-I mRNA expression in Mx-cKO
compared to both types of control cells (CT and Alb-cKO) at all
doses tested (Figure 4C). For example, at 10 ng/ml of TGF-b
there was 5-fold induction in Mx-cKO cells compared to 2-fold
induction in CT cells in relative mRNA expression of collagen-
Figure 2. Induction of liver fibrosis. Fibrosis was induced in control mice (CT) and in conditional knockout mice in which fibronectin was deleted
upon activation of the Mx promoter (Mx-cKO) using dimethylnitrosamine (DMN), and healthy littermate CT and cKO mice were treated with normal
saline (NaCl 0.9%) instead. (A) ELISA of circulating fibronectin to confirm deletion in Mx-conditional knockout mice (Mx-cKO). N=16 per group. (B)
Representative Western blot for fibronectin in liver tissue from fibrotic and healthy mice showing the absence of a signal for fibronectin in Mx-cKO
mice. Equal protein amounts as determined by BCA measurements were loaded on the gel. (C) Fibronectin ELISA of liver lysates showing an increase
in fibronectin in fibrotic CT mice compared to healthy CT mice but no significant increase in fibrotic Mx-cKO mice compared to healthy Mx-cKO mice.
(D) Upper panel: Sirius-red staining of the extracellular matrix suggesting an increase in matrix accumulation in fibrotic Mx-cKO mice. Bars represent
50 mm. Lower panel: Morphometric analysis of the fibrotic area on three sections per mouse. N=6–9 mice/group. (E) Upper panel: Collagen-type-I
staining by immunofluorescence showing an increase in staining in fibrotic Mx-cKO mice. Bars represent 100 mm. Lower panel: Collagen (determined
by measuring hydroxyproline) is increased in livers of fibrotic Mx-cKO mice (1.6-fold increase in fibrotic Mx-cKO mice compared to fibrotic controls).
Of note, healthy Mx-cKO mice already show a significant increase in collagen, when compared to healthy CT (1.3-fold increase), albeit at lower
amounts than fibrotic mice. Triplicate measurements were performed/mouse. N=5–14 mice/group. (F) No difference in the total number of
apoptotic cells is found between CT mice and Mx-cKO mice, as determined by TUNEL staining to identify apoptotic cells (in green) and nuclei (DAPI in
blue). Upper panel: Examples of areas that were TUNEL stained in fibrotic CT and Mx-cKO mice. Bars represent 200 mm. Lower panel: Quantification of
the number of apoptotic cells. 3 sections/mouse were analyzed. N=3 mice/group.
doi:10.1371/journal.pone.0028181.g002
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B were performed in Alb-cKO mice lacking fibronectin in the hepatocytes only in order to determine whether the absence of fibronectin in
hepatocytes affects the degree of fibrosis. Experiments shown in panels C–F were performed in Mx-cKO mice lacking fibronectin in both hepatocytes
and stellate cells to determine which cell type is involved in increased matrix production (shown in figures 2D and 2E). Experiments in Alb-cKO
mice: (A) ELISA for circulating fibronectin shows that deletion of fibronectin in hepatocytes only by using the albumin promoter to drive cre
expression (Alb-cKO) results in decreased circulating fibronectin levels in Alb-cKO mice. Fibrosis does not result in an increase in the amount of
circulating fibronectin in CT or Alb-cKO compared to healthy mice of the same genotype. The same relationship was true for Mx-cKO mice (shown in
Figure 2A). N=7–8 mice/group. (B) Collagen quantification based on hydroxyproline measurements shows that collagen increases in fibrotic animals
but unlike Mx-cKO mice (Figure 2E) there is no difference between fibrotic Alb-cKO and fibrotic CT animals in the absence of fibronectin in
hepatocytes only. Triplicate measurements/mouse were performed. N=11–13 mice/fibrotic group and 3 mice/healthy group. Experiments
performed in Mx-cKO mice lacking fibronectin production in both the hepatocytes and the stellate cells: (C) Administration of plasma fibronectin
(pFN) at the same time as fibrosis induction does not affect the degree of fibrosis in CT mice or Mx-cKO mice. Mice received daily injections of
fibronectin (1 mg/mouse) beginning one day before start of fibrosis induction with DMN. Mice were euthanized after 4 weeks of experimental fibrosis
and collagen content in the liver was quantified. N=4 mice/group. (D) The number of inflammatory cells is similar between fibrotic mice lacking
fibronectin in hepatocytes and stellate cells (Mx-cKO) and fibrotic controls. Upper panel: Representative pictures showing almost equivalent numbers
of inflammatory cells (stained with CD45
+) in the two fibrotic groups and in the two healthy groups. Bars represent 100 mm. Lower panel:
Quantification of the number of CD45
+ cells. N=3 mice/group. (E) Increased number of a-SMA stained cells and hence activated stellate cells in
fibrotic Mx-cKO mice compared to fibrotic controls. Upper panel: Representative pictures showing increased a-SMA stained cells in Mx-cKO mice
compared to controls in both the healthy and the fibrotic groups. Bars represent 100 mm. Lower panel: There is a significant increase in the number of
a-SMA positive cells in the absence of fibronectin in stellate cells (in Mx-cKO mice). N=4 mice/group. (F) Proliferation of stellate cells in Mx-cKO mice
is increased. Co-staining of liver sections with ki-67 (to identify proliferating cells) in red and GFAP (to identify stellate cells) in green was performed.
Upper panel: A single cell is enlarged to show how the cells were analyzed. Only cells stained positive for GFAP and showing the characteristic pink
color in the overlay of ki-67 and DAPI were counted as proliferating stellate cells. Lower panel: More proliferation was found in fibrotic Mx-cKO mice.
N=3–4 mice/group.
doi:10.1371/journal.pone.0028181.g003
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PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e28181Figure 4. Expression of collagen-type-I mRNA and TGF-b signal transduction in stellate cells in vitro. Hepatic stellate cells were isolated
from control mice and Mx-cKO mice in which fibronectin was deleted in vivo, and cultured on plastic with media containing fibronectin-depleted FCS.
(A) Expression of a-SMA increases significantly in Mx-cKO stellate cells compared to CT cells (FN fl/fl) and Alb-cKO cells (Alb-cre FN fl/fl) after 24 hours
and increases further after 48 hours in culture (Note the different scales on the three segments of the left y axis). (B) Baseline (unstimulated) collagen-
type-I mRNA expression is increased in stellate cells isolated from conditional knockout mice (Mx-cKO) when compared to controls (CT and Alb-cKO)
as detected by quantitative real time PCR (qPCR) collected from cells after 24 hours in culture. (C) Stimulation with up to 10 ng/ml TGF-b for 24 hours
results in more pronounced collagen-type-I mRNA expression in Mx-cKO cells. (D) SMAD3 translocation is increased in both untreated and stimulated
cKO cells. SMAD3 translocation from the cytoplasm to the nucleus was examined in cells left untreated (baseline) for 26 hours after isolation or
stimulated with 10 ng/ml TGF-b added 24 hours after culture and left 2 hours on the cells. SMAD3 staining is shown in red and the DAPI-stained
nuclei are presented in green. Whenever translocation takes place nuclei are stained yellow due to the overlay of SMAD3 and DAPI. Upper panels:
More translocation of SMAD3 takes place in Mx-cKO stellate cells compared to CT at baseline (no TGF-b treatment) and after TGF-b stimulation. Bars
represent 20 mm. Lower panel: Graph of the percentage of yellow nuclei in CT (two bars on the left) and cKO cells (on the right) left untreated (white
bars) and after stimulation with TGF-b (grey bars). N=6 wells/group from three experiments. (E) PDGF-BB increases collagen-type-I mRNA expression
in both Mx-cKO and CT cells, but does not result in increased collagen mRNA expression in cKO compared to CT cells, while TGF-b does. Isolated
stellate cells were cultured for 24 hours on plastic then stimulated with either 100 ng/ml PDGF-BB or 10 ng/ml TGF-b for 24 hours. Collagen mRNA
expression in untreated cells was normalized to 1 for both TGF-b and PDGF experiments to simplify comparison. N= at least 5 wells/condition. (F)
Inhibition of TGF-b signaling (SB431542) results in normalization of the response to TGF-b in cKO cells; there is no significant difference between CT
and Mx-cKO cells that were pretreated with the inhibitor and TGF-b (p=NS). Cells were treated for one hour with 10 mM of the inhibitor, followed by
10 ng/ml of TGF-b in the presence of the inhibitor. Collagen-type-I mRNA expression was determined in cells collected 2 hours after the addition of
TGF-b. Data shown represent the fold induction in response to either TGF-b or the inhibitor followed by TGF-b after adjustment to baseline (no TGF-b
treatment) for ease of comparison. N=7-9 wells/group. Baseline data are presented in Figure S7. (G) TGF-b-receptor-II relative mRNA expression is
significantly increased in Mx-cKO stellate cells stimulated with 10 ng/ml of TGF-b for 24 hours compared to CT cells. N=6 wells/group. (H) TGF-b-
receptor-I relative mRNA expression is similar between stimulated Mx-cKO and CT stellate cells in vitro. N=6 wells/group.
doi:10.1371/journal.pone.0028181.g004
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In contrast, stimulation of hepatocytes with TGF-b failed to show
an increase in collagen-type-I expression or a difference between
Mx-cKO and CT cells at the three doses tested (data not shown).
Lastly, stimulation of either Kupffer cells or endothelial cells failed
to show a difference in the response to TGF-b between CT and
Mx-cKO cells (Figures S5 and S6). This shows that the absence of
fibronectin increases the responsiveness of stellate cells to TGF-b
stimulation.
Specificity of increased responsiveness of cKO cells. We
then sought to determine whether the increase in responsiveness of
cKO cells was specific for TGF-b, and therefore performed three
sets of experiments. In the first set of experiments, we examined
whether the increase in responsiveness to TGF-b is translated into
increased intracellular signaling specific for TGF-b. Therefore,
translocation of SMAD3 to the nucleus was studied [18,19]. At
baseline the percentage of nuclei in which SMAD3 translocation
to the nucleus took place (shown as yellow due to overlay of red
SMAD3 and green DAPI staining) was higher in cKO cells
(baseline CT: 8% vs. cKO: 16%, p,0.005). Consistently, after
stimulation more translocation took place in cKO cells (CT: 32%
vs. cKO: 49%, p,0.0001 for CT and cKO compared to the
respective baseline and p,0.005 compared to each other)
(Figure 4D).
In the second set of experiments we sought to determine
whether cytokines other than TGF-b cause increased collagen
mRNA expression in cKO cells. Neither treatment with PDGF-BB
nor EGF reproduced the effects seen with TGF-b (Figure 4E and
data not shown).
In the third set of experiments TGF-b signaling was inhibited in
both CT and cKO cells to determine whether a more pronounced
inhibition ensued in cKO cells. Adding an inhibitor of TGF-b
signaling (SB431542) to cKO cells one hour before treating with
TGF-b resulted in a significant decrease in collagen-type-I mRNA
expression compared to TGF-b treatment alone in both CT and
cKO cells (p,0.05, Figure 4F). Furthermore, the inhibitor resulted
in collagen expression in inhibitor-treated cKO cells that was
equivalent to inhibitor-treated CT cells (p=NS, Figure 4F).
Unstimulated cells showed similar relationships (Figure S7).
We then asked whether this specific response was associated
with increased TGF-b-receptor mRNA expression. Indeed, we
found that the relative mRNA expression of TGF-b-receptor-II
increased in stimulated cKO cells in vitro (Figure 4G) while the
relative mRNA expression of TGF-b-receptor-I (Alk-5) was not
significantly altered between cKO and CT cells in vitro (Figure 4H).
In summary, the increase in responsiveness in cKO was specific
for TGF-b as was shown in three different experiments.
TGF-b amounts in cKO stellate cells. Because of increased
responsiveness of cKO cells at baseline we sought to examine
whether TGF-b amounts were different between cKO and CT
cells. Active TGF-b protein concentrations in conditioned media
from hepatic stellate cells cultured for 24 hours on plastic without
stimulation were increased in Mx-cKO cells compared to CT as
determined by ELISA and confirmed in a bioassay (p,0.05,
Figure 5A and data not shown). The amounts of total TGF-b
(including matrix TGF-b) were not significantly different between
both groups and consequently the percentage of active to total
TGF-b was significantly increased in Mx-cKO cells (Figure 5B).
This increase could not be directly attributed to an increase in
TGF-b mRNA amounts, since TGF-b relative mRNA expression
was similar between cKO and CT cells (p=NS, Figure 5C).
Establishing a causal relationship between increased
active TGF-b levels and increased responsiveness to TGF-
b. The finding of an increase in active TGF-b levels does not
explain why stellate cells lacking fibronectin exhibit increased
sensitivity compared to control cells when stimulated with
equivalent concentrations of TGF-b in vitro (as shown in
Figure 4C). To address this we sought to determine whether
TGF-b signaling and collagen-type-I mRNA expression and
consequently responsiveness of cKO stellate cells could be
affected by increased exposure to TGF-b. In fact, a positive
feedback loop of TGF-b on the stellate cells has been proposed
[20]. We therefore examined in vitro whether repeated exposure of
wildtype stellate cells to TGF-b leads to increased TGF-b-
receptor-II mRNA expression and SMAD3 translocation to the
nucleus, which then in turn will lead to increased collagen-type-I
expression. Increased TGF-b-receptor-II mRNA expression and
SMAD3 translocation were more pronounced after three expo-
sures to TGF-b (-24, -8, -4 hours) than after a single exposure
(-4 hours) (p,0.05, Figures 5D and 5E). This was associated
with an increase in collagen-type-I mRNA expression (p,0.05,
Figure 5F). These findings thus suggest that an increase in avai-
lable active TGF-b is associated with increased responsiveness of
stellate cells to TGF-b.
Changes in TGF-b protein amounts and signaling in cKO
mice
Based on the described in vitro experiments, increased collagen
production by the cKO stellate cells was due to an increase in
active TGF-b and hence increased responsiveness of these cells. In
order to determine whether an increase in available TGF-b was
the culprit for boosted fibrosis in Mx-cKO mice, total TGF-b
content in fibrotic-Mx-cKO and fibrotic-CT livers was determined
by treating mechanically disrupted liver lysates with hydrochloric
acid (HCl) to release all TGF-b including matrix-bound TGF-b.
However, no difference could be detected (p=NS, Figure 6A). In
contrast, active TGF-b in liver lysates was increased in the livers of
fibrotic Mx-cKO mice as measured by ELISA (p,0.05, Figure 6B).
Because TGF-b that is bound to the latency-associated peptide
and hence is inactive, can be detected by antibodies used in ELISA
tests, we performed a bioassay that detects only free unbound
TGF-b [21]. Similar relationships were obtained (data not shown).
The increase in the amount of active TGF-b was associated with
enhanced TGF-b-receptor-II expression by Western blotting in
livers from fibrotic Mx-cKO mice (Figures 6C and 6D) but no
change in TGF-b-receptor-I expression in vivo (Figure S8). TGF-b
signaling was also augmented as evidenced by increased SMAD3
phosphorylation in fibrotic Mx-cKO livers in vivo shown by
Western blotting (Figures 6E and 6F). Presumably this ultimately
led to boosted collagen production shown in Figure 2E. Hence,
these in vivo findings replicate the findings in stellate cells in vitro
and implicate the increase in active TGF-b as the culprit for
enhanced collagen production in fibrotic Mx-cKO mice.
The role of the presence of fibronectin around the cells
The previous data suggest that the absence of fibronectin in the
matrix surrounding the stellate cells leads to increased active TGF-
b and increased responsiveness of cKO stellate cells. Thus one
would expect that the presence of fibronectin in the surrounding of
the stellate cells would have two consequences: first, it will result in
a decrease in active TGF-b in the media and second, it should
protect the cKO cells from excessive stimulation by TGF-b. Wells
were therefore pre-coated with fibronectin. The amount of active
TGF-b in the conditioned media of stellate cells cultured for
24 hours on fibronectin decreased significantly both in control
cells (p,0.05), and in cKO cells (p,0.05, Figure 7A). Thus
coating with fibronectin reduced the amount of active TGF-b in
the media of cKO cells, but did not completely normalize it.
Fibronectin and Liver Fibrosis
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cultured on plastic (p,0.05). The second consequence, namely that
fibronectin coating should lead to normalization of the responsive-
ness of cKO cells was also confirmed. The TGF-b-induced increase
in mRNA expression of TGF-b-receptor-II and collagen type I was
blunted in cKO cells cultured on fibronectin (uncoated vs. coated
Mx-cKO: p,0.05, coated cKO vs. coated CT: p=NS, coated
cKOvs.CTonplastic:p=NS,Figures7Band7C).Thesedatathus
show a complete restoration of normal responsiveness of cKO cells
in the presenceoffibronectin inthe cell surrounding. Thiseffect was
specific for fibronectin, because coating with collagen failed to affect
the amount of collagen-type-I mRNA expression in CT or cKO
cells after stimulation (Figure 7D).
In order to determine whether the formation of fibrils was
enough to normalize the response of stellate cells to TGF-b we
used stellate cells from mice that express only one fibronectin gene
with a mutated RGD binding domain [22]. These cells were
obtained from mice with the following genotype: Mx-cre/- FN-
RGE/fl. Activating Mx-cre results in deletion of the floxed
fibronectin allele, and the stellate cells can only produce
fibronectin that is able to form fibrils but is unable to activate
integrins via RGD (RGE/-). Treatment of these cells with TGF-b
failed to induce an increased response, as measured by collagen-
type-I mRNA expression compared to CT (Figure 7E). This
suggests normalization of the response of stellate cells to TGF-b.
Indeed, the concentration of active TGF-b in the conditioned
media from untreated stellate cells was similar between the cells
that produce normal fibronectin (CT) and those that produce the
mutated fibronectin (RGE/-) (Figure 7F). This indicates that
binding of fibronectin to integrins through the RGD domain is not
required for normalization of the stellate cells response to TGF-b,
while providing fibronectin fibrils is enough for normalization of
the response.
Based on these findings we conclude, that the presence of
fibronectin fibrils in the matrix surrounding stellate cells
significantly diminishes the amount of active TGF-b released
and restores a normal response to TGF-b.
Discussion
The principal findings of this study are: 1) Deletion of
fibronectin in the liver results in increased collagen at baseline
Figure 5. TGF-b content and signaling in vitro. (A) Active TGF-b is increased in conditioned media from unstimulated Mx-cKO stellate cells in
culture compared to CT cells. After isolation, stellate cells were cultured for 24 hours on plastic, media were then changed and conditioned media
(using fibronectin-depleted serum) were collected after an additional 24 hours. Active TGF-b was determined by ELISA in the media. Total protein
was determined in cell lysates. N=7 wells/group. (B) The amount of active TGF-b corrected to total TGF-b was increased in Mx-cKO cultures because
total TGF-b did not differ in both groups (Data not shown). Active TGF-b was determined in the conditioned media and total TGF-b was determined
in the medium together with the cell layer. N=10 CT and 8 Mx-cKO pairs. (C) No difference in relative TGF-b mRNA expression by qPCR between
untreated Mx-cKO and CT cells is found. N=10 wells/group. (D) Repeated exposure to 10 ng/ml TGF-b increases TGF-b-receptor-II mRNA expression
in wild-type stellate cells in culture compared to one time exposure only. (222): Cells cultured for 24 hours (time 0) were left untreated for an
additional 24 hours, (22 +): Cells were left untreated at time 0 and 16 hours later, and were stimulated with TGF-b at 20 hours. Cells were stained
and mRNA collected after 24 hours, (+++ ): Cells were stimulated with TGF-b at time 0 and then after 16 and 20 hours, and cells were stained and
mRNA collected after 24 hours. N=5 wells/condition. (E) Same experimental design was used as in D, and the graph shows that repeated exposure
to TGF-b results in increased SMAD3 translocation to the nucleus. N=4 wells/condition. (F) Same experimental design was used as in D, and the
graph shows that repeated exposure to TGF-b results in increased collagen-type-I mRNA expression in comparison to one time exposure only. N=5
wells/condition.
doi:10.1371/journal.pone.0028181.g005
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of fibronectin in hepatic stellate cells leads to increased collagen-
type-I at baseline and after activation. 3) These effects are
associated with increased active TGF-b protein and cellular
response to TGF-b, are mediated by the SMAD pathway, are not
due to increased TGF-b mRNA expression, but are associated
with increased TGF-b-receptor-II mRNA expression. 4) Inhibiting
TGF-b signaling or providing fibronectin to stellate cells in vitro
normalizes the heightened responsiveness of cKO stellate cells.
The increase in fibrosis in mice lacking fibronectin in the liver is
thus due to an increase in active TGF-b, most likely resulting from
a failure to incorporate TGF-b in the matrix in the absence of
fibronectin. These findings show that in vitro fibronectin production
by hepatic stellate cells is critical for modulating the amount of
available bioactive TGF-b and hence the cell responsiveness to
TGF-b. This offers a possible explanation for the in vivo finding
that the presence of fibronectin seems to protect against
exacerbation of fibrosis.
Fibronectin is required in vitro for the assembly of a collagen
matrix [5,6]. In its absence a reduction in collagen matrix
assembly would be expected. This, however, was not the case in
our model. Immunohistochemistry of liver sections (data not
shown) and ELISA data (Figure 2C) show a residual amount of
fibronectin in the matrix, despite the deletion of fibronectin in the
circulation and stellate cells by .95%. Presumably, this residual
amount originates from the time before induced deletion of
fibronectin at 4 weeks postnatally, and might be sufficient to
support collagen assembly. It is also possible, that despite the
apparent successful deletion of fibronectin the remaining un-
deleted circulating fibronectin is enough to support normal
collagen matrix assembly even though it is much diminished,
since circulating fibronectin contributes to tissue fibronectin
[7,23]. A related issue is whether the decrease in the amount of
surrounding fibronectin may modulate the synthesis of collagen.
Our in vitro data show that this is the case since cKO stellate cells
unable to produce fibronectin showed a decrease in collagen
Figure 6. TGF-b content and signaling in vivo after induction of liver fibrosis in CT and Mx-cKO mice. (A) Total TGF-b in liver lysates was
similar between CT and Mx-cKO mice. TGF-b was determined using a commercial assay, and corrected to total protein determined by BCA as
described in the methods. N=6/group. (B) Active TGF-b was increased in Mx-cKO livers in comparison to CT. Active TGF-b was determined using liver
lysates from the same mice as above and corrected to total protein. (C) TGF-b-receptor-II protein expression is increased in liver tissue from fibrotic
Mx-cKO mice compared to fibrotic CT mice. A Western blot is shown for a representative pair with b-tubulin used as a loading control. (D)
Densitometry for protein expression of TGF-b-receptor-II in liver tissue from fibrotic Mx-cKO and CT mice corrected to b-tubulin. N=6/group. (E)
Protein expression of phosphorylated SMAD3 is increased in fibrotic Mx-cKO livers compared to CT in vivo. Shown is a representative pair suggesting
increased phospho-SMAD3 in cKO in vivo (from top: phospho-SMAD3, total SMAD3, and b-tubulin). (F) Densitometry for phospho-SMAD3 in Western
blotting shows an increase in phospho-SMAD3 when corrected to b-tubulin. N=6/group.
doi:10.1371/journal.pone.0028181.g006
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to cells cultured on plastic (Figure 7C). Unfortunately, the degree
of deletion of circulating fibronectin using the albumin promoter
at 91% was less pronounced than using the Mx promoter at 97%
in relation to control mice. Theoretically this residual circulating
fibronectin might have been enough and hence could have
resulted in equivalent degrees of fibrosis in hepatocyte specific
conditional knockouts and their controls, but this is unlikely
because we could not detect a dose response effect of circulating
fibronectin on fibrosis, and normalizing circulating levels of
fibronectin failed to prevent the enhanced fibrosis in Mx-cKO
mice compared to fibrotic CT mice. Another cell type that is
affected by the deletion of fibronectin using the Mx-promoter is
the endothelial cell. Sinusoidal endothelial cells exert a profibrotic
effect particularly in the early stages of liver fibrosis [24]. It has
been shown that early in fibrosis these cells produce a fibronectin
isoform called EDA fibronectin that can be detected in sinusoids in
vivo as well as in vitro in endothelial cell cultures. Furthermore,
endothelial cells in culture form a fibronectin matrix that
accelerates hepatic stellate cell activation [24]. Based on these
findings one would have expected a decrease in stellate cell
activation in the absence of fibronectin in endothelial cells, and not
an increase as presented here. On the other hand, it is conceivable
that the absence of fibronectin production by the endothelial cells
using the Mx-promoter contributed to the increase in bioavailable
TGF-b. At any rate our data clearly implicate the stellate cells both
in vivo and in vitro as a culprit for increased collagen production in
our model.
Figure 7. Fibronectin normalizes the responsiveness of cKO cells. (A) Active TGF-b in the medium decreases significantly both in control and
Mx-cKO cells in the presence of fibronectin coating. Stellate cells were cultured directly after isolation for 24 hours on plates left uncoated or coated
with fibronectin, media were changed and collected after an additional 24 hours in culture (using 10% fibronectin-depleted FCS). N=5 wells/group.
(B) Fibronectin coating is associated with a decrease in TGF-b-receptor-II mRNA expression in response to TGF-b stimulation in Mx-cKO cells. Isolated
cells were cultured on plastic or on fibronectin for 24 hours, then left untreated or treated with 10 ng/ml TGF-b for an additional 24 hours after which
mRNA was collected. Data presented are adjusted to unstimulated cells to facilitate comparison. N=6/group. (C) Fibronectin coating normalizes the
response of cKO cells to TGF-b stimulation. No difference in the responsiveness to TGF-b stimulation in the presence of fibronectin coating between
CT and Mx-cKO cells is seen, while cKO cells cultured on plastic show a higher responsiveness to TGF-b than CT cells on plastic. Cells were cultured
and data are presented as in B. N=6/group. (D) Collagen coating does not affect the response of cells to TGF-b. Therefore, cKO cells continue to show
an increase in responsiveness to TGF-b that is unrelated to the presence or absence of collagen coating. Cells were cultured and data are presented
as in B. N=4/group. (E) The presence of fibronectin fibrils with mutated RGD domain and hence unable to activate integrins via RGD is enough to
result in normal amounts of collagen production in response to TGF-b stimulation. Deletion of fibronectin in mice with the genotype Mx-cre/- FN-
RGE/fl resulted in cells that only express one mutated fibronectin (RGE/-). Cells were treated with TGF-b and collagen-type-I examined by qPCR. N=6–
7/group. (F) The presence of fibronectin with an RGE mutation is enough to normalize the levels of active TGF-b in the conditioned media. Cells were
cultured as in A. N=6–7/group.
doi:10.1371/journal.pone.0028181.g007
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differ in their characteristics from plasma fibronectin [3]. While
plasma fibronectin represents the soluble form of fibronectin, the
three isoforms produced by the stellate cells belong to the group of
cellular isoforms that are also viewed as being insoluble, since they
are found in high concentrations in the tissue. These three
isoforms are: EDA, EDB and oncofetal fibronectin (oFN) (defined
by an O-glycosylation site in the variable region) [3,25,26]. Only
little of these isoforms escapes from the matrix and can be detected
in the circulation [27], while plasma fibronectin has no
demonstrable role in the formation of fibrosis in any reported
model. Under certain circumstances plasma fibronectin is involved
in extracellular matrix integrity [25,28], and a number of in vitro
studies examining the role of fibronectin in collagen matrix
assembly have used plasma fibronectin despite the presence of one
report suggesting that the absence of extra-domain-B (EDB) results
in fibronectin fibrils that are thinner and shorter [29]. Differences,
however, have been reported for the effects on the cells. The EDB
domain has been shown to support the proliferation of fibroblasts
[29]. The presence of extra-domain-A (EDA) has been implicated
in upregulating binding affinity to a5b1-integrin and integrin-
mediated signal transduction [8,30]. It has also been identified as a
binding domain for a4b1-integrin [31]. Even though the
possibility that an isoform of fibronectin, other than plasma
fibronectin may normally inhibit stellate cells cannot be excluded,
we are not aware of data to support such a conclusion. If anything
there are reports that the presence of fibronectin containing the
EDA domain resulted in activation, instead of inhibition of hepatic
stellate cells in vitro [24,32]. Together these data support an
indirect effect of fibronectin with regards to TGF-b regulation.
An increase in active TGF-b in the absence of an adequate
fibronectin matrix can explain all our findings starting with the
increase in baseline production of collagen-tsype-I in healthy as
well as in fibrotic Mx-cKO mice, the increase in active stellate cell
numbers, and finally the increase in TGF-b signaling [2,33]. At
first glance it may seem surprising that fibronectin is able to blunt
the response to TGF-b. It has been unequivocally shown however,
that fibronectin plays two roles in TGF-b modification. On the
one hand, it is required for the incorporation of TGF-b bound to
the latent TGF-b binding protein-1 (LTBP-1) in the matrix [34],
and on the other hand, it is required for the avb6-integrin
mediated activation of TGF-b stored in the matrix [35]. Our in
vitro data show an increase at baseline in bioactive TGF-b without
an associated increase in TGF-b mRNA in cKO stellate cells.
Thus the data suggest that the incorporation of TGF-b in the
matrix, and not the production of TGF-b is abnormal resulting in
an increase in the amount of available TGF-b. The fact that total
TGF-b was similar between CT and cKO fibrotic livers suggests
that in the absence of fibronectin in stellate cells total TGF-b is
irrelevant to the pathophysiology of fibrosis. It also appears that
the total amount of TGF-b is not modulated by the amount of free
TGF-b since in the CT livers 7% of the total TGF-b consisted of
active TGF-b, while in cKO livers the percentage was 17%.
Recently accepted but not yet published work by Moriya et al.
[36] used a similar model and focused on matrix assembly. While
we found that there was significant induction of collagen
production in Mx-cKO mice at baseline and after DMN and
CCl4 administration (Figure 2E and data not shown), Moriya et al.
found no difference either at baseline or after CCl4 treatment.
Since our finding was reproducible and could be confirmed using
two different models of fibrosis induction we currently lack an
explanation for this discrepancy. Both works complement each
other in that Moriya et al. imply that TGF-b stimulates matrix
assembly, while we established both in vivo and in vitro that the
amount of active TGF-b originating from the stellate cells is at
least partially responsible for increased matrix production in a
fibronectin-deficient state.
In summary, our data support the conclusion that in healthy
and injured liver, stellate cells require adequate amounts of matrix
fibronectin in order to buffer the amount of bioavailable TGF-b
and its fibrogenic outcome.
Materials and Methods
Mice
Mice possessing an inducible Mx promoter or an albumin
promoter driving cre-recombinase expression were crossed with
mice carrying loxP-flanked (floxed) fibronectin (FN-fl/fl) or mice
carrying a fibronectin gene with a mutated RGD to RGE
sequence in the integrin binding domain and the floxed gene on
the second allele (FN-RGE/fl) [15,22,37]. Mx was induced at 4
weeks of age using 250 mg polyinosinic-polycytidylic acid (pIpC)
injected three times over one week as described [15]. Animals used
were of the C57Bl/6 background. Fibronectin in plasma or liver
lysates was determined by ELISA [25].
Induction of liver fibrosis
Liver fibrosis was induced by injecting dimethylnitrosamine
(DMN) intraperitoneally at 10 mg DMN/g body weight (Sigma-
Aldrich) 3x/week for 4 weeks in male mice [13]. Mice in the Mx
group started induction of liver fibrosis at the age of 8-9 weeks
while mice in the Alb group started induction at the age of 9–11
weeks. Human plasma fibronectin isolated from outdated plasma
as described was administered i.p. at a dose of 1 mg/mouse/d
[25,38]. The studies in mice were approved by the animal
protection committee of the University of Heidelberg #ma34050,
#ma35590, #ma36955, and #A-18/09. Thus, all animal work
was conducted according to relevant national and international
guidelines.
Determination of the degree of fibrosis
Morphometric analysis of areas stained with sirius-red was
performed using the program ImageJ (Wayne Rasband, NIH).
Hydroxyproline was measured using a biochemical method as
published [39,40]. To calculate the amount of collagen, we
multiplied measured hydroxyproline content by 10 as proposed by
Berg in 1982 [39]. Liver enzymes alanine aminotransferase (ALT)
and aspartate aminotransferase (AST) were measured in serum
using routine clinical chemistry.
Cell culture
Hepatic stellate cells, Kupffer cells and endothelial cells were
isolated from Mx-conditional knockout mice (Mx-cKO) which
carry the Mx-promoter attached to cre and are homozygous for
the floxed fibronectin gene [15,37]. For some experiments mice
that carry Mx-cre, a mutated fibronectin gene that contains an
RGE domain instead of the RGD domain and a floxed fibronectin
gene were used (Genotype: Mx-cre/- FN-RGE/fl) [22]. In all Mx
mice the Mx promoter was activated in vivo prior to cell isolation as
described [10]. Cells from littermates lacking the Mx-cre gene or
carrying the Alb-cre gene together with two floxed fibronectin
genes were used as controls. Briefly, the liver was perfused and the
cells were separated using Nycodenz (Axis-shield) as described
[41]. Cells were cultured in DMEM and 10% fibronectin-depleted
fetal-calf-serum (FCS) [10]. Depletion of FCS was performed by
running FCS on gelatine-sepharose columns 3-5 times. Final
concentration of fibronectin was 8-11 ng/ml in the batches used.
All experiments were started 24 hours after isolation. Unless noted
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platelet derived growth factor-BB (PDGF-BB) (100 ng/ml) (Sigma-
Adrich) or murine epidermal growth factor (EGF) (100 ng/ml)
(Peprotech). The TGF-b signaling inhibitor (SB431542) (Merck)
was used at a final concentration of 10 mM [42]. Treatment with
TGF-b1, PDGF-BB or EGF lasted for 24 hours or as described in
the figure legends, and treatment with the inhibitor lasted one
hour, after which TGF-b was added and left for an additional
2 hours before collecting the samples. Fibronectin used for coating
was isolated from outdated human plasma as described [25], and
collagen was from human placenta (Sigma-Aldrich). Both were
added at 100 mg/ml overnight, because it has been reported that
high concentrations of collagen are associated with stimulation of
stellate cells [43].
DNA analysis
DNA was isolated from stellate cells using proteinase K and
nested PCR was performed using the following primer pairs
consecutively: fibronectin forward-59-TCGCACCCGCTGCGC-
TGCA-39, reverse-59-ATTGTCAAAACAGCCAGCTGCGA-39,
and then forward-59-AGGGTGTGAGCCGGACAACT-39, re-
verse-59-CAACTGACTTGGTGAGCCTGCA-39.
RNA analysis
RNA was isolated using RNeasy (Qiagen). Quality was tested
using RNA-6000-Pico-Chip (Agilent). Reverse transcription was
performed using iScript-Select (BioRad). The following primer
pairs were used: fibronectin forward-5 `-GTCAGTGTCTCCAGT-
GTCTAC-39, reverse-59-TGGCTTGCTGGCCAATCAGT-39,
desmin forward-59-CTGGAGGCTTGGGGTCGC-39, reverse-
59-CGGATCTCCTCTTCATGCAC-39, glial fibrillary acidic
protein (GFAP) forward-59-AGCGAGCGTGCAGAGATGAT-
39, reverse-59- CCGAGGTCCTGTGCAAAGT-39, GAPDH
forward-59-TGAAGGTCGGTGTGAACGGATTT-39, reverse-
59-CATGTAGGCCATGAGGTCCAC-39.
Quantitative real time PCR (qPCR) products were obtained
using LightCycler and TaqMan probes, and results were nor-
malized to hypoxanthine-phosphoribosyltransferase (HPRT) after
standard curves were established. The choice of HPRT for
normalization was based on early experiments showing compara-
ble expression between CT and Mx-cKO liver. Data were
evaluated using RelQuant (Roche). The primers used were those
suggested by the universal primer library from Roche. The probes
were as follows: Collagen-type-I and TGF-b1 probe #15, HPRT
probe #95, TGF-b-receptor-I probe#32, TGF-b-receptor-II
probe#7, a-SMA probe #21, C-terminal fibronectin probe
#66, EDA fibronectin probe #76, and EDB fibronectin probe
#31.
TGF-b ELISA and bioassay
Mouse TGF-b1 was determined using an ELISA kit from
Promega and confirmed using a bioassay. This was done because
the ELISA antibodies may detect TGF-b that is bound to the
latency-associated peptide (LAP), and hence inactive. In the
bioassay mink lung epithelial cells (MLEC) stably transfected with
an expression construct containing a truncated PAI-1 promoter
fused to the firefly luciferase reporter gene are responsive only to
free active TGF-b, and hence this assay by virtue of its design only
detects bioavailable TGF-b.
Conditioned media from stellate cells in culture for 24 hours
were used to determine active TGF-b. This was diluted 1:5 for the
commercial assay and 1:4 for the bioassay. In order to determine
total TGF-b in vitro stellate cell plates were heated to 80uC for
10 minutes and then placed on ice. Supernatants including the
lysed cells were then assayed (using the kit) or added to the
reporter cells in a dilution of 1:4 (100 ml) for 5 hours and luciferase
assayed as described [21]. Bioluminescence was measured in white
plates using Wallac-Victor2-1420 (Perkin-Elmer). The amount of
active or total TGF-b was then corrected to total protein measured
using the BCA kit (Pierce).
In order to determine TGF-b in liver tissue using the
commercial assay, liver pieces (50-100 mg in 300 ml DPBS) were
mechanically disrupted using a Hybaid-Ribolyser-cell-disrupter,
half was then treated with HCl followed by neutralization with
NaOH as suggested in the manual to determine total TGF-b. The
other half was used without HCl treatment to determine active
TGF-b and total protein. Both treated and untreated samples were
tested at a final dilution of 1:10. For the bioassay, liver pieces were
disrupted in 500 ml DMEM, half was centrifuged at 13000 RPM
for 15 minutes and supernatant used for measuring active TGF-b
and total protein, and the second half was heated to 80uC for
10 minutes followed by 10 minutes on ice and 1 minute cen-
trifugation. The supernatant was then used for total TGF-b and
total protein determinations. Liver lysates were diluted 1:400.
Bioluminescence was measured as described above and corrected
to total protein.
Staining protocols and immunohistochemistry
Extracellular matrix was stained using picro-sirius-red in 5 mm
frozen sections of the liver as reported [44]. Cells or liver sections
were fixed in 4% paraformaldehyde or ice-cold acetone. The
following antibodies were used: rabbit anti-GFAP-IgG (Acris);
mouse anti-desmin-IgG (AbD Serotec); rat anti-CD45-IgG and
mouse anti-ki-67-IgG conjugated with alexa-555 (BD Pharmin-
gen); rat anti-F4/80 (E-Bioscience); rabbit anti-cleaved caspase 3
(ASP175) conjugated with alexa-488 (Cell Signaling); mouse anti-
a-SMA-IgG conjugated with Cy3 (Sigma-Aldrich); rabbit anti-
SMAD3-IgG (Cell Signaling); rabbit anti-mouse fibronectin
(Millipore); rabbit anti collagen-type-I (Abcam); goat anti-rabbit
conjugated with Cy2; goat anti-rabbit conjugated with alexa-555
(Molecular Probes); goat anti-mouse-IgG conjugated with Cy2
(Dianova), and goat anti-rat-IgG conjugated with Cy2 (Dianova).
Slides were photographed in the Nikon Imaging Center
(University of Heidelberg) and processed using ImageJ (Wayne
Rasband, NIH). TUNEL was performed according to the manu-
facturer’s recommendations (Trevigen). Endothelial cells were
stained by adding Dil-AcLDL (Invitrogen) at a concentration of
10 mg/ml to living cells for 4 hours at 37uC. Quantification was
performed in at least three sections per mouse in at least three
mice per group or more as noted in the figure legends. At least 200
positive cells were counted per section and then corrected to the
area examined.
Western blotting and immune precipitation
Fibronectin and SMAD3 were detected using the same
antibodies as above. In addition, the following antibodies were
used: anti-TGF-b-receptor-II (Abcam); anti-TGF-b-receptor-I (R-
20) (Santa Cruz); rabbit anti-phospho-SMAD3-IgG (Cell Signal-
ing), and anti-b-Tubulin (Sigma-Aldrich). Western blotting of
fibronectin in stellate cells in vitro was preceded by immune
precipitation, which was performed using gelatine-sepharose beads
added to equivalent protein amounts of cell lysates from cKO and
CT cells for 1 hour. After washing, Laemmli buffer was added to
the coated beads, which were boiled before being applied to the
gel. The beads did not require coating with an antibody because of
the avid binding of fibronectin to them. All antibodies were diluted
in 5% BSA, except fibronectin which was diluted in 5% milk
powder/tris-buffered saline.
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Analyses were performed using SPSS (V14.0) and first applying
ANOVA tests when appropriate. Comparisons were then
performed using Student’s t-test or Wilcoxon paired test as
appropriate. Results are expressed as mean6standard-error-of-
the-mean (M6SEM).
Supporting Information
Figure S1 Expression of C-terminal fibronectin and the
EDA and EDB domains in fibrotic livers of CT and Mx-
cKO mice. Relative mRNA expression in the liver of fibrotic CT
and Mx-cKO mice was determined by quantitative real time PCR
for C-terminal fibronectin, EDA, and EDB domains. The percent
values over Mx-cKO bars show the relative remaining expression
of mRNA for the three products.
(TIF)
Figure S2 Effect of fibrosis on the circulating levels of
AST and ALT. Despite the more pronounced increase in
collagen in fibrotic Mx-cKO mice there is no difference in liver
enzymes AST or ALT between fibrotic Mx-cKO mice and fibrotic
CT mice reflecting absence of a more pronounced increase in
necrosis of hepatocytes in fibrotic Mx-cKO mice.
(TIF)
Figure S3 Normalization of circulating levels of fibro-
nectin in Mx-cKO mice, in which fibrosis was induced
and which received daily injections of fibronectin at
1 mg/mouse/day in comparison to control mice (CT) in
which fibrosis was induced, but which did not receive
daily fibronectin injections. Blood was drawn and tested 10
days after the start of injection. N=4/group.
(TIF)
Figure S4 Apoptosis of stellate cells is similar between
fibrotic CT and fibrotic Mx-cKO mice lacking fibronec-
tin. Liver sections were co-stained with TUNEL (to detect
apoptotic cells) and GFAP (to detect stellate cells). Quantification
of the percent apoptotic stellate cells revealed no difference
between the two fibrotic groups or between the two healthy
groups. At least 1800 cells were counted per mouse in the fibrotic
groups, and 800 cells in the healthy groups. 3 mice were analyzed
per group.
(TIF)
Figure S5 Deletion of fibronectin in Kupffer cells does
not result in increased responsiveness to TGF-b. Cells
were left untreated or treated on the same day of isolation with
10 ng/ml of TGF-b in medium with 10% fibronectin-depleted
FCS. Twenty four hours later RNA was collected and qPCR was
performed. Results are expressed as fold increase over baseline.
N=6/group.
(TIF)
Figure S6 Deletion of fibronectin in endothelial cells
does not result in increased responsiveness to TGF-b.
Isolated endothelial cells were left untreated or treated on the day
following isolation with 10 ng/ml of TGF-b in medium with 10%
fibronectin-depleted FCS. Twenty four hours later RNA was
collected and qPCR was performed. Results are expressed as fold
increase over baseline. N=6/group.
(TIF)
Figure S7 Effect of inhibiting TGF-b-receptor-I on
baseline collagen-type-I mRNA expression. Adding an
inhibitor of TGF-b-receptor-I (SB-431542) to cKO cells resulted
in a significant decrease in baseline collagen-type-I mRNA
production by 50% (p,0.05) compared to untreated cKO cells,
while collagen mRNA expression failed to show a significant
difference between untreated CT cells and those treated with the
inhibitor only. Furthermore, no significant difference in baseline
collagen mRNA expression is found between CT cells treated with
the inhibitor only and cKO cell treated with the inhibitor only.
Cells were cultured for 24 hours on plastic after isolation, either
left untreated or treated with 10 mM of the inhibitor and collected
3 hours later. N=8 wells/group for CT cells and 6 wells/group
for cKO cells.
(TIF)
Figure S8 TGF-b-receptor-I protein expression in liver
tissue from fibrotic Mx-cKO mice is not increased
compared to liver tissue from fibrotic CT mice. (A)
shows a representative pair from a Western blot for TGF-b-
receptor-I. b-tubulin was used as a loading control. (B) shows
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